RA0453

antibody from Oursmab

Targeting: LAG3 CD223

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0453

Provider

Oursmab

Product name

Favezelimab (Biosimilar Reference Antibody) (LAG3)

Antibody type

Monoclonal

Description

Favezelimab (development code MK-4280) is an investigational, humanized monoclonal IgG4 antibody being developed for cancer immunotherapy. It functions as an antagonist of the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. By binding with high affinity to LAG-3 on the surface of T cells and other immune cells, favezelimab blocks its interaction with major histocompatibility complex class II (MHC-II) molecules and other potential ligands. This blockade releases the inhibitory "brake" that LAG-3 imposes on T-cell activation, proliferation, and effector function, thereby aiming to restore and enhance anti-tumor immune responses, particularly in T cells that are exhausted or dysfunctional. Its IgG4 isotype is chosen to minimize effector functions that could deplete immune cells.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.